Cellular responses to EGFR inhibitors and their relevance to cancer therapy

This publication has 113 references indexed in Scilit:

• Treatment of HNSCC cell lines with the EGFR‐specific inhibitor cetuximab (Erbitux^®) results in paradox phosphorylation of tyrosine 1173 in the receptor
  FEBS Letters, 2006
• Protein kinase Cδ signaling downstream of the EGF receptor mediates migration and invasiveness of prostate cancer cells
  Biochemical and Biophysical Research Communications, 2006
• Epidermal growth factor receptor (EGFR) signaling in cancer
  Gene, 2005
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
  The Lancet, 2005
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004
• Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin
  Oncogene, 2004
• The EGFR family and its ligands in human cancer
  European Journal Of Cancer, 2001
• Platelet-Derived Growth Factor-BB, Insulin-like Growth Factor-I, and Phorbol Ester Activate Different Signaling Pathways for Stimulation of Vascular Smooth Muscle Cell Migration
  Experimental Cell Research, 1998